Literature DB >> 21346041

Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection.

Christine C Roberts1, Ryan Swoyer, Janine T Bryan, Frank J Taddeo.   

Abstract

Real-time human papillomavirus (HPV) type-specific multiplex PCR assays were developed to detect HPV DNA in specimens collected for the efficacy determination of the quadrivalent HPV (type 6, 11, 16, and 18) L1 virus-like particle (VLP) vaccine (Gardasil). We evaluated the concordance between type-specific multiplex HPV PCR and the widely used, commercially available Roche Linear Array genotyping PCR assay. Female genital swab specimens were tested for the presence of L1, E6, and E7 sequences of HPV type 6 (HPV6), HPV11, HPV16, HPV18, HPV31, HPV45, HPV52, and HPV58 and E6 and E7 sequences of HPV33, HPV35, HPV39, HPV51, HPV56, and HPV59 in type- and gene-specific real-time multiplex PCR assays. Specimens were also tested for the presence of L1 sequences using two versions of the Roche Linear Array genotyping assay. Measures of concordance of a modified version of the Linear Array and the standard Linear Array PCR assay were evaluated. With specimen DNA extraction using the Qiagen Spin blood kit held as the constant, multiplex PCR assays detect more HPV-positive specimens for the 14 HPV types common to both than either version of the Linear Array HPV genotyping assay. Type-specific agreements between the assays were good, at least 0.838, but were often driven by negative agreement in HPV types with low prevalence, as evidenced by reduced proportions of positive agreement. Overall HPV status agreements ranged from 0.615 for multiplex PCR and standard Linear Array to 0.881 for multiplex PCR and modified Linear Array. An alternate DNA extraction technique, that used by the Qiagen MinElute kit, impacted subsequent HPV detection in both the multiplex PCR and Linear Array assays.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346041      PMCID: PMC3122643          DOI: 10.1128/JCM.00235-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens.

Authors:  J U Cope; A Hildesheim; M H Schiffman; M M Manos; A T Lörincz; R D Burk; A G Glass; C Greer; J Buckland; K Helgesen; D R Scott; M E Sherman; R J Kurman; K L Liaw
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Evaluation of commercial kits for the detection and typing of human papillomavirus in cervical swabs.

Authors:  S Venturoli; F Bonvicini; M Cricca; G Gallinella; F Giosa; F Farinazzo; G Stefanuto; M Musiani; M Zerbini
Journal:  J Virol Methods       Date:  2002-08       Impact factor: 2.014

3.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

4.  A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears.

Authors:  Mark Schiffman; Cosette M Wheeler; Abhijit Dasgupta; Diane Solomon; Philip E Castle
Journal:  Am J Clin Pathol       Date:  2005-11       Impact factor: 2.493

5.  Screening for genital human papillomavirus: results from an international validation study on human papillomavirus sampling techniques.

Authors:  S de Sanjosé; X F Bosch; N Muñoz; S Chichareon; C Ngelangel; L Balagueró; M V Jacobs; C J Meijer; J M Walboomers
Journal:  Diagn Mol Pathol       Date:  1999-03

6.  Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens.

Authors:  K Husnjak; M Grce; L Magdić; K Pavelić
Journal:  J Virol Methods       Date:  2000-08       Impact factor: 2.014

7.  Importance of specimen type in detecting human papillomavirus DNA from the female genital tract.

Authors:  Christine C Roberts; Kai-Li Liaw; Finn Egil Skjeldestad; Kathrin U Jansen; Janine T Bryan
Journal:  J Med Virol       Date:  2009-09       Impact factor: 2.327

8.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

9.  A direct comparison of methods proposed for use in widespread screening of human papillomavirus infections.

Authors:  P Gravitt; A Hakenewerth; J Stoerker
Journal:  Mol Cell Probes       Date:  1991-02       Impact factor: 2.365

10.  Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies.

Authors:  C L Peyton; M Schiffman; A T Lörincz; W C Hunt; I Mielzynska; C Bratti; S Eaton; A Hildesheim; L A Morera; A C Rodriguez; R Herrero; M E Sherman; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

View more
  9 in total

1.  The 2010 global proficiency study of human papillomavirus genotyping in vaccinology.

Authors:  Carina Eklund; Ola Forslund; Keng-Ling Wallin; Tiequn Zhou; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients.

Authors:  Emmanouela Sarchianaki; Stavros P Derdas; Markos Ntaoukakis; Elena Vakonaki; Eleni D Lagoudaki; Ismini Lasithiotaki; Anna Sarchianaki; Anastasios Koutsopoulos; Emmanouil K Symvoulakis; Demetrios A Spandidos; Katerina M Antoniou; George Sourvinos
Journal:  Tumour Biol       Date:  2013-12-06

Review 3.  Immobilization techniques for microarray: challenges and applications.

Authors:  Satish Balasaheb Nimse; Keumsoo Song; Mukesh Digambar Sonawane; Danishmalik Rafiq Sayyed; Taisun Kim
Journal:  Sensors (Basel)       Date:  2014-11-25       Impact factor: 3.576

4.  Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana.

Authors:  Dorcas Obiri-Yeboah; Yaw Adu-Sarkodie; Florencia Djigma; Kafui Akakpo; Ebenezer Aniakwa-Bonsu; Daniel Amoako-Sakyi; Simpore Jacques; Philippe Mayaud
Journal:  Gynecol Oncol Res Pract       Date:  2017-03-03

5.  Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries.

Authors:  Susanne K Kjaer; Mari Nygård; Karin Sundström; Joakim Dillner; Laufey Tryggvadottir; Christian Munk; Sophie Berger; Espen Enerly; Maria Hortlund; Ágúst Ingi Ágústsson; Kaj Bjelkenkrantz; Katrin Fridrich; Ingibjorg Guðmundsdóttir; Sveinung Wergeland Sørbye; Oliver Bautista; Thomas Group; Alain Luxembourg; J Brooke Marshall; David Radley; Yi Shen Yang; Cyrus Badshah; Alfred Saah
Journal:  EClinicalMedicine       Date:  2020-06-20

6.  Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up.

Authors:  Susanne K Kjaer; Mari Nygård; Karin Sundström; Christian Munk; Sophie Berger; Mensur Dzabic; Katrin Elisabeth Fridrich; Marianne Waldstrøm; Sveinung Wergeland Sørbye; Oliver Bautista; Thomas Group; Alain Luxembourg
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

7.  Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.

Authors:  Vasiliki Michopoulou; Stavros P Derdas; Emmanouil Symvoulakis; Nikolaos Mourmouras; Alexandros Nomikos; Dimitris Delakas; George Sourvinos; Demetrios A Spandidos
Journal:  Tumour Biol       Date:  2014-09-12

8.  Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.

Authors:  Lone K Petersen; Jaime Restrepo; Edson D Moreira; Ole-Erik Iversen; Punnee Pitisuttithum; Pierre Van Damme; Elmar A Joura; Sven-Erik Olsson; Daron Ferris; Stan Block; Anna R Giuliano; Xavier Bosch; Sophie Pils; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Donna Hyatt; Roger Maansson; Erin Moeller; Hong Qi; Christine Roberts; Alain Luxembourg
Journal:  Papillomavirus Res       Date:  2017-03-16

9.  Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.

Authors:  S M Garland; P Pitisuttithum; H Y S Ngan; C-H Cho; C-Y Lee; C-A Chen; Y C Yang; T-Y Chu; N-F Twu; R Samakoses; Y Takeuchi; T H Cheung; S C Kim; L-M Huang; B-G Kim; Y-T Kim; K-H Kim; Y-S Song; S Lalwani; J-H Kang; M Sakamoto; H-S Ryu; N Bhatla; H Yoshikawa; M C Ellison; S R Han; E Moeller; S Murata; M Ritter; M Sawata; C Shields; A Walia; G Perez; A Luxembourg
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.